<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/357ACFC3-42A0-4060-8C2C-D5977482CF0E"><gtr:id>357ACFC3-42A0-4060-8C2C-D5977482CF0E</gtr:id><gtr:firstName>Anderson</gtr:firstName><gtr:otherNames>Joseph</gtr:otherNames><gtr:surname>Ryan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12006"><gtr:id>336486AD-2741-4F14-9BF9-B1DAFD2097E0</gtr:id><gtr:title>Targeted therapy in molecular subgroups of lung cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12006</gtr:grantReference><gtr:abstractText>Lung cancer is a devastating disease and the leading cause of cancer death worldwide. Patients with early stage disease can be treated with surgery or radiotherapy. However, most patients are diagnosed with disease that has already spread locally and/or distally and, in these cases, chemotherapy with or without radiotherapy forms the cornerstone of treatment. Unfortunately, the prognosis for patients with locally advanced or metastatic lung cancer is extremely poor. Even when the disease is diagnosed early it recurs locally or distally in a significant proportion of patients. Despite substantial morbidity and mortality, lung cancer remains relatively neglected in basic research. However, there is an emerging growth in our understanding of the molecular heterogeneity of the disease in the clinic. This project aims to identify and evaluate novel therapies and targets for their potential to improve outcomes in lung cancer. In particular we aim to identify novel approached that can improve the effectiveness of radiotherapy by using preclinical studies to identify the most promising approaches for future clinical development</gtr:abstractText><gtr:technicalSummary>There have been some significant recent improvements in the treatment of lung cancer, in particular through targeting tumour stroma (blood vessels; through VEGFR-signalling inhibition), and tumours harbouring activating somatic mutations (EGFR and, more recently, ALK). However these advances have been largely limited to metastatic disease where the only significant role of radiotherapy is for symptom palliation. In lung cancer, the major disease settings for the therapeutic uses of radiation include (i) early disease for patients who are not candidates for surgery, (ii) locally advanced disease either alone or, more usually, in combination with chemotherapy, and (iii) treatment of isolated tumour metastases, for example in the brain. This research programme aims to use non-clinical studies to identify and prioritise new treatment options for possible clinical testing and, in particular, to identify those approaches with the greatest potential to improve radiotherapy treatment outcomes. To support this research programme, a range of model systems will be used, focused initially on non-small cell lung cancer (NSCLC). For in vitro studies, a diverse panel of NSCLC lines previously characterised for baseline gene expression and common somatic mutations has been established that broadly represents the spectrum of histologies found in NSCLC patients. This panel will be used for evaluating pharmacological and phenotypic effects within tumour cells in subsets of cell lines that represent molecularly distinct patient subsets in the clinic. A range of in vivo models will be established to determine the biological and potential clinical relevance of in vitro observations. Three biologically and clinically relevant models of lung cancer will used to support this project: models of (i) early disease (autochthonous tumours - carcinogen-induced tumours and mice genetically engineered to develop lung cancer), (ii) locally advanced disease (human tumour cells implanted as xenografts into the lung), and (iii) isolated metastases (human tumour cells implanted as xenografts into the brain). The in vitro cell lines, and in vivo models constitute an experimental platform that will be used to evaluate new targets, novel therapies and radiation combination therapies in NSCLC, and is anticipated to provide significant opportunities for collaborative studies both within the Institute and more widely. The initial focus of research is to identify novel drug targets with the potential to improve the curative potential of radiation therapy. An additional focus is to seek novel combination therapies to improve the cell killing effects of molecularly targeted therapies that are currently used in advanced disease.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3434000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>37E68099-3BEA-4E6B-B39A-F017C52AF6C3</gtr:id><gtr:title>PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a546ddf78c5ee61a6f66d5eaea4d30c3"><gtr:id>a546ddf78c5ee61a6f66d5eaea4d30c3</gtr:id><gtr:otherNames>Lourenco LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5a9590bb14f421.88818566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E0AC7EB-5F92-408E-9B6C-FE56DDF3C3C3</gtr:id><gtr:title>BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53e022313482229f623b560769057735"><gtr:id>53e022313482229f623b560769057735</gtr:id><gtr:otherNames>Tacconi EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5a959157ed21e6.36218403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8729D112-84C2-48CB-8CBC-0BC36105F925</gtr:id><gtr:title>Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c41b8d059958eda786b850b7642d33b3"><gtr:id>c41b8d059958eda786b850b7642d33b3</gtr:id><gtr:otherNames>Burrell JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14030_20_22290271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AC32ADF-9487-4B77-9113-E656CE179B0C</gtr:id><gtr:title>Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79b689c7a0e4d8c783e7a21adaec3610"><gtr:id>79b689c7a0e4d8c783e7a21adaec3610</gtr:id><gtr:otherNames>Zimmer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>56afc607b1f314.59547101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6948A7D2-DFF8-4725-BBEB-8736FB4339F1</gtr:id><gtr:title>Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.</gtr:title><gtr:parentPublicationTitle>Thyroid : official journal of the American Thyroid Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d212a3f85693694e11d0f8af8bdee77"><gtr:id>9d212a3f85693694e11d0f8af8bdee77</gtr:id><gtr:otherNames>Broutin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1050-7256</gtr:issn><gtr:outcomeId>pm_14030_20_23822199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B53B966-172F-435E-87A0-DA4A2AEB0205</gtr:id><gtr:title>Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>56afc6627e8379.66238214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4989677-DFC7-4E48-A954-BCABD47755B0</gtr:id><gtr:title>Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80aef585e94cf6d5924ff590e3804d8a"><gtr:id>80aef585e94cf6d5924ff590e3804d8a</gtr:id><gtr:otherNames>Wells SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_14030_20_22025146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>715969FC-B8DB-479C-B9BF-18A2AA7CF8B2</gtr:id><gtr:title>Replication stress and chromatin context link ATM activation to a role in DNA replication.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2090f8066bac9da54ba42ea076759ab5"><gtr:id>2090f8066bac9da54ba42ea076759ab5</gtr:id><gtr:otherNames>Olcina MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>54491ce0c000d8.44876167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69EE502C-7E2F-4D9C-86A7-37B535E82B22</gtr:id><gtr:title>An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2aec95396df7fe6c95bc8c9e7657731f"><gtr:id>2aec95396df7fe6c95bc8c9e7657731f</gtr:id><gtr:otherNames>Stead LF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_14030_ne_0078823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCB9EC8A-78CE-4E7D-8C6C-C2329C086F0D</gtr:id><gtr:title>Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9949f9eafe0438c21b6167cd384cbf83"><gtr:id>9949f9eafe0438c21b6167cd384cbf83</gtr:id><gtr:otherNames>Bokobza SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>54491b063019b5.66509026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>330B43A9-8539-4478-8B7E-939E12476341</gtr:id><gtr:title>Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a153f6e7ebfa9dfb489a058607fffd1"><gtr:id>2a153f6e7ebfa9dfb489a058607fffd1</gtr:id><gtr:otherNames>Alferez DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>pm_14030_20_22858681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24280B23-CDB3-48A2-BB9A-5D90C595A839</gtr:id><gtr:title>ATM and ATR as therapeutic targets in cancer.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d31f42f277849f02ec524cfe003f0aa8"><gtr:id>d31f42f277849f02ec524cfe003f0aa8</gtr:id><gtr:otherNames>Weber AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>doi_55f985985e280e48</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA38A73E-231A-4047-BD23-9E1B24B6999B</gtr:id><gtr:title>Abstract B30: Novel targets for combination therapy in EGFR mutated NSCLC</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/768626717143036f27221d9c518f2da6"><gtr:id>768626717143036f27221d9c518f2da6</gtr:id><gtr:otherNames>Drobnitzky N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9592a3eb7065.98216869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7DABFB1-41C1-448A-A545-2100AF488BF9</gtr:id><gtr:title>False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/058a95503988c4d3230f1706a0fdf676"><gtr:id>058a95503988c4d3230f1706a0fdf676</gtr:id><gtr:otherNames>Boult JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14030_20_22596237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED4BCF3D-1C11-468E-91A4-2559CBBACFE0</gtr:id><gtr:title>Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/def889d634876aed959bcdfc347694de"><gtr:id>def889d634876aed959bcdfc347694de</gtr:id><gtr:otherNames>Damaraju VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>54491cdf29ace9.85805155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E855876D-2E8F-4855-9AB0-E2F9B9AC0E15</gtr:id><gtr:title>Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98056804c494d3414810be8f51f23282"><gtr:id>98056804c494d3414810be8f51f23282</gtr:id><gtr:otherNames>Takahashi O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14030_20_22275507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E901F97B-E084-4861-AA50-7811A201083E</gtr:id><gtr:title>Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.</gtr:title><gtr:parentPublicationTitle>Thyroid : official journal of the American Thyroid Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d212a3f85693694e11d0f8af8bdee77"><gtr:id>9d212a3f85693694e11d0f8af8bdee77</gtr:id><gtr:otherNames>Broutin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1050-7256</gtr:issn><gtr:outcomeId>54491ce0718bd5.08562134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2AEBACD-1969-4247-AB20-C608A85B81EF</gtr:id><gtr:title>Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.</gtr:title><gtr:parentPublicationTitle>Lung cancer (Amsterdam, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7d6414b5561959e026a21adb7b56753"><gtr:id>f7d6414b5561959e026a21adb7b56753</gtr:id><gtr:otherNames>Jiang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0169-5002</gtr:issn><gtr:outcomeId>564f1367c43528.27892704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F827E271-3796-4CED-8146-D6782D69BEE6</gtr:id><gtr:title>Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7d6414b5561959e026a21adb7b56753"><gtr:id>f7d6414b5561959e026a21adb7b56753</gtr:id><gtr:otherNames>Jiang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>56afc585a700f1.31722082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D07C398A-D750-4D4A-BC3C-4F0395594DFF</gtr:id><gtr:title>KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db6297050bb8f31010f9d6b4bdf10968"><gtr:id>db6297050bb8f31010f9d6b4bdf10968</gtr:id><gtr:otherNames>Nilsson MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>564f1367f14758.57469907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68BFFD4C-E09B-46CD-9E55-2C593B29D569</gtr:id><gtr:title>EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5be6e80208f25950b565ff536158d0c"><gtr:id>a5be6e80208f25950b565ff536158d0c</gtr:id><gtr:otherNames>Heymach JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>54491c53c10b08.38371256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0997C75C-2F1B-4573-B0AC-E0F2E3F4B109</gtr:id><gtr:title>The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b197b49fac390505e597222eb8e679"><gtr:id>e8b197b49fac390505e597222eb8e679</gtr:id><gtr:otherNames>Cascone T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a9591b3583164.12461137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D685C42-CCF8-45CF-8683-7B59BA3DC451</gtr:id><gtr:title>Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b726aa3136763436d0a9e4f3aaeff"><gtr:id>667b726aa3136763436d0a9e4f3aaeff</gtr:id><gtr:otherNames>Devery AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>564f13678ffd66.52625401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2F82DF5-1BBD-48A4-9FCE-32A64BB78A44</gtr:id><gtr:title>Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9949f9eafe0438c21b6167cd384cbf83"><gtr:id>9949f9eafe0438c21b6167cd384cbf83</gtr:id><gtr:otherNames>Bokobza SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>54491b0669d3e9.61254332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61DB68E8-6DFB-4990-AF7C-1A9E863C200B</gtr:id><gtr:title>TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722bec08d1ae0b6ca0835b0496f2c666"><gtr:id>722bec08d1ae0b6ca0835b0496f2c666</gtr:id><gtr:otherNames>Pirovano G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5a9591f36d1372.62943184</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12006</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>